209394-18-3

209394-18-3 structure

Name: Ladostigil hydrochloride
Chemical Name: Ladostigil hydrochloride
CAS Number: 209394-18-3
Molecular Formula: C₁₆H₂₁ClN₂O₂
Molecular Weight: 308.80
Catalog: Signaling Pathways Neuronal Signaling AChE
Create Date: 2023-04-25 19:10:04
Modify Date: 2024-01-09 20:01:01
Ladostigil (TV-3326) hydrochloride is an orally active dual inhibitor of cholinesterase and brain-selective monoamine oxidase (MAO), with IC50s of 37.1 and 31.8 μM for MAO-B and AChE, respectively. Ladostigil hydrochloride exhibits neuroprotective, antioxidant and anti-inflammatory activities. Ladostigil can be used for the research of depression and Alzheimer's disease[1][2].

Name	Ladostigil hydrochloride

Description	Ladostigil (TV-3326) hydrochloride is an orally active dual inhibitor of cholinesterase and brain-selective monoamine oxidase (MAO), with IC50s of 37.1 and 31.8 μM for MAO-B and AChE, respectively. Ladostigil hydrochloride exhibits neuroprotective, antioxidant and anti-inflammatory activities. Ladostigil can be used for the research of depression and Alzheimer's disease[1][2].
Related Catalog	Signaling Pathways >> Neuronal Signaling >> Monoamine Oxidase Research Areas >> Neurological Disease Signaling Pathways >> Neuronal Signaling >> AChE
Target	AChE:31.8 μM (IC50) MAO-B:37.1 μM (IC50)
In Vitro	Ladostigil (1-10 µM) hydrochloride 具有神经保护活性，包括防止线粒体膜电位 (ψ) 下降，衰减凋亡级联和抑制 OS 损伤诱导的 ROS 产生[2]。 Ladostigil (1-10 µM) hydrochloride 具有显著的神经保护活性，包括抑制 caspase-3 激活，诱导 Bcl-2，降低人成神经细胞瘤 SK-N-SH 细胞中 Bad 和 Bax 基因和蛋白的表达[2]。
In Vivo	Ladostigil (17 mg/kg; p.o. daily for 6 weeks) hydrochloride 在从青春期到产前压力大鼠的成年期的高架十字迷宫 (EPM) 和强迫游泳测试 (FST) 测试中，消除了他们的高度焦虑和抑郁样行为[4]。 Ladostigil (50 μmol/kg; single p.o.) hydrochloride 在大鼠物体识别测试中恢复丧失的情景记忆[3]。 Animal Model: Pathogen-free (SPF) Sprague-Dawley rats[4] Dosage: 17 mg/kg Administration: Oral (added to the drinking water) daily for 6 weeks Result: Inhibited brain MAO-A and B by more than 60%. Reduced hyperanxiety of male and female prenatally stressed (PS) rats in the EPM and depressive-like behaviour in the FST.
References	[1]. Denya I, et, al. Design, synthesis and evaluation of indole derivatives as multifunctional agents against Alzheimer's disease. Medchemcomm. 2018 Jan 16; 9(2):357-370. [2]. Weinreb O, et, al. Ladostigil: a novel multimodal neuroprotective drug with cholinesterase and brain-selective monoamine oxidase inhibitory activities for Alzheimer's disease treatment. Curr Drug Targets. 2012 Apr; 13(4): 483-94. [3]. Weinstock M, et, al. Ladostigil, a novel multifunctional drug for the treatment of dementia co-morbid with depression. J Neural Transm Suppl. 2006; (70):443-6. [4]. Poltyrev T, et, al. Effect of chronic treatment with ladostigil (TV-3326) on anxiogenic and depressive-like behaviour and on activity of the hypothalamic-pituitary-adrenal axis in male and female prenatally stressed rats. Psychopharmacology (Berl). 2005 Aug;181(1): 118-25.

Molecular Formula	C₁₆H₂₁ClN₂O₂
Molecular Weight	308.80

209394-18-3	1406-14-0
6138-79-0	127228-87-9
143851-98-3	929-73-7
65546-09-0	1135280-78-2
56-99-5	1406-02-6
445479-12-9	72374-31-3
1158522-08-7	940364-43-2
134104-43-1	131615-57-1
6906-52-1	930439-75-1
1018584-77-4	1375289-11-4